Aytu Biopharma (AYTU) Work In Process (2021 - 2026)

Aytu Biopharma (AYTU) has 6 years of Work In Process data on file, last reported at $2.0 million in Q1 2026.

• Work In Process for Q1 2026 came in at $2.0 million, down 0.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (down 0.63% YoY), and the FY2025 annual result was $1.4 million, down 75.88% from the prior year.
• Work In Process advanced to $2.0 million in Q1 2026 per AYTU's latest filing, from $1.8 million in the prior quarter.
• Over five years, Work In Process peaked at $5.7 million in Q2 2024 and troughed at $862000.0 in Q3 2025.
• A 5-year average of $2.7 million and a median of $2.7 million in 2023 frame the typical range for Work In Process.
• The sharpest annual moves came in 2024 and 2025: Work In Process soared 93.67% in 2024, then plunged 75.88% in 2025.
• A 5-year view of Work In Process shows it stood at $2.8 million in 2022, then decreased by 4.6% to $2.7 million in 2023, then rose by 16.04% to $3.1 million in 2024, then tumbled by 41.48% to $1.8 million in 2025, then advanced by 12.72% to $2.0 million in 2026.
• Business Quant data shows AYTU's Work In Process at $2.0 million in Q1 2026, $1.8 million in Q4 2025, and $862000.0 in Q3 2025.